Neil B Goldstein

US Patent:

6365157, Apr 2, 2002

Filed:

Sep 22, 1999

Appl. No.:

09/401163

Inventors:

Patricia Rockwell - West Readding CT
Neil I. Goldstein - Maplewood NJ

Assignee:

ImClone Systems, Inc. - New York NY

International Classification:

A01N 3718

US Classification:

4241561, 4241381, 4241431, 514 2, 435330, 435334

Abstract:

Monoclonal antibodies that specifically bind to an extracellular domain of a flt-1 receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.

US Patent:

6413717, Jul 2, 2002

Filed:

Mar 18, 1998

Appl. No.:

09/040981

Inventors:

Yilong Sun - Fort Lee NJ
Paul B. Fisher - Scarsdale NY
Neil I. Goldstein - Maplewood NJ

Assignee:

Corixa Corporation - Seattle WA

International Classification:

C12Q 168

US Classification:

435 6, 435 912

Abstract:

Methods are provided for identifying agents that modulate the expression of genes, such as genes encoding tumor suppressor or tumor-promoting proteins. The methods generally comprise screening candidate agents for the ability to enhance expression of a tumor suppressor gene, such as mda-7, or for the ability to inhibit expression of a tumor-promoting gene within a cell. Modulating agents may be used, for example, within anti-cancer therapies.

US Patent:

6448077, Sep 10, 2002

Filed:

Nov 10, 1997

Appl. No.:

08/967113

Inventors:

Patricia Rockwell - West Redding CT
Neil I. Goldstein - Maplewood NJ

Assignee:

ImClone Systems, Inc. - New York NY

International Classification:

C12N 506

US Classification:

435334, 435328, 5303873, 5303881, 53038822

Abstract:

Chimeric and humanized monoclonal antibodies that specifically bind to an extracellular domain of a VEGF receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.

US Patent:

6811779, Nov 2, 2004

Filed:

Mar 2, 2001

Appl. No.:

09/798689

Inventors:

Patricia Rockwell - West Redding CT
Neil I. Goldstein - Maplewood NJ

Assignee:

ImClone Systems Incorporated - New York NY

International Classification:

A61K 39395

US Classification:

4241351, 4241421, 4241431, 4241551, 4241741

Abstract:

The invention provides a method of reducing tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and radiation. In addition, the invention provides a method of reducing tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and a chemotherapeutic agent.

US Patent:

7060808, Jun 13, 2006

Filed:

Jun 7, 1996

Appl. No.:

08/973065

Inventors:

Neil I. Goldstein - Maplewood NJ, US
Nicholas A. Giorgio - New York NY, US
Steven Tarran Jones - Radlett, GB
Jose William Saldanha - Enfield, GB

Assignee:

ImClone Systems Incorporated - New York NY

International Classification:

C07H 21/04

US Classification:

536 231, 536 2353, 5303873, 53038885, 435 691, 435 696, 435325, 4352523

Abstract:

A nucleic acid is provided which encodes a humanized antibody or fragment thereof, which encodes a protein which binds to human EGF-receptor. Monoclonal antibody 225 is the complementary determining region (CDR) donor.

US Patent:

20020192213, Dec 19, 2002

Filed:

Mar 4, 2002

Appl. No.:

10/090711

Inventors:

Patricia Rockwell - West Redding CT, US
Neil Goldstein - Maplewood NJ, US

International Classification:

A61K039/395
C12P021/02
C12N005/06
C07K016/30
C07H021/04
C12P021/06
C12N015/00
C12N015/09
C12N015/63
C12N015/70
C12N015/74
C12N005/16
C07K016/00
C12P021/08

US Classification:

424/143100, 435/069100, 435/334000, 435/320100, 536/023530, 530/388220

Abstract:

Monoclonal antibodies that specifically bind to an extracellular domain of a flt-1 receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.

US Patent:

20030108545, Jun 12, 2003

Filed:

Mar 4, 2002

Appl. No.:

10/091300

Inventors:

Patricia Rockwell - West Redding CT, US
Neil Goldstein - Maplewood NJ, US

International Classification:

A61K039/395

US Classification:

424/143100, 424/145100

Abstract:

The present invention provides a method of reducing or inhibiting tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and radiation, chemotherapy, and/or an additional receptor antagonist.

US Patent:

20030219821, Nov 27, 2003

Filed:

May 6, 2002

Appl. No.:

10/139732

Inventors:

Paul Fisher - Scarsdale NY, US
Neil Goldstein - Maplewood NJ, US

International Classification:

G01N033/53
C07H021/04
C12P021/02
C12N005/06
C07K016/30

US Classification:

435/007100, 435/069100, 435/326000, 435/320100, 530/388800, 536/023530

Abstract:

This invention provides a method for preparing antibodies directed against a protein associated with a cancer, comprising the steps of: (a) transfecting non-tumorigenic cells with a cDNA library comprising cDNA molecules derived from mRNA of cancer cells; (b) masking the transfected cells with antibodies raised against non-tumorigenic cells transfected with a cDNA library derived from normal cells; and (c) generating antibodies against the masked cells, and thereby generating antibodies directed against a protein associated with a cancer.